Deqi Pharmaceutical-B (06996): Sivio®'s application for supplementary marketing of the new drug with the third indication was approved by the Ministry of Food and Drug Safety of Korea

Zhitongcaijing · 10/17 22:57

According to Zhitong Finance App, Deqi Pharmaceutical-B (06996) announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved a new drug supplementary marketing application (SnDA) for the treatment of adult patients with multiple myeloma (MM) who have received at least one treatment in the past.